12/10/2017 20:50:00

CAPS® to Showcase Latest 503B Quality Assurance Capabilities and Expansion Plans at Health Connect Reverse Expo – Fall Hospital Pharmacy Conference

IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS®), will showcase its sustained commitment to improving patient safety at the 2017 Health Connect Conference in Chicago, IL, Oct. 16-18.

At booth #508, CAPS representatives will introduce the company’s latest 90-Day Beyond Use Dating (BUD) quality assurance offering for pre-filled syringes and other products, which is designed to improve the waste reduction process. This initiative further complements CAPS’ current extended BUD offerings. 

CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act. During the conference, CAPS will highlight its Test, Hold and ReleaseSM (THR®) program, which is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for 100% cGMP release testing for sterility, potency, and endotoxin prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.

“Our existing high quality standards are strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that 100% release testing from our 503B facilities is the only way to assure the level of quality demanded by our customers.”

CAPS was among the first outsourcing admixture pharmacies in the nation to fully adopt release testing.

“CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment,” said Koch. “Our goal is to provide our customers with programs such as THR, and extended BUD to help them focus on improving patient care.” 

To further underscore its commitment to servicing its customers and expanding its sterile compounding outsourcing services in the U.S., CAPS will open a new 250,000 square-foot, state-of-the-art facility in Phoenix, AZ, which is expected to open in the summer of 2018. The new facility will be registered with the FDA as a 503B outsourcing facility, to distribute compounded sterile preparations. CAPS has two existing 503B facilities located in San Diego, CA and Allentown, PA.

“With the opening of our third 503B facility, CAPS will enhance productivity and increase capacity, while serving as an economic boost to the local and state economy,” said Tom Wilverding, President of CAPS. “When fully operational the CAPS facility will create nearly 400 new jobs including opportunities for pharmacists, pharmacy technicians, chemists, microbiologists, and other support personnel.”

About B. Braun

B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

About CAPS

CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS currently has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.CAPSpharmacy.com.

Contact:    

Todd Jones

Central Admixture Pharmacy Services, Inc. 303.744.7713

Todd.Jones@CAPSpharmacy.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 Feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
30
21 Feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
25
21 Feb
GEN
Du bliver da dummere og dummere at høre på 
21
17 Feb
MAERSK-B
Jeg er i mit vemodige hjørne i dag, for det er den første dag i over 25 år, hvor jeg ikke kan kalde ..
20
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
20
17 Feb
E:QEC
Med fare for en gentagelse, så vil jeg alligevel melde at Canada er i fuld gang med at omstille sig ..
18
17 Feb
NOVO-B
@alpenyt Tror bare jeg vil kalde dig for Wiki(pedia) fra nu af :) Du burde skrive en artikel i kvart..
17
16 Feb
NOVO-B
Jeg deltager, modsat dig, med argumenter og fakta, du er blot personfnidrer, fordi du ikke kan forst..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Rovio Entertainment Corp.: PRELIMINARY INFORMATION ABOUT 2017 Q4 AND FULL-YEAR RESULTS AND OUTLOOK FOR 2018
2
Rome’s falling artefacts, solo travel and more in the latest issue of Business Destinations
3
Publication of Industrivärden’s 2017 Annual Report and Sustainability Report
4
Northland Power Delivers Excellent 2017 Results With Gross Profit Up 37% and Adjusted EBITDA Up 22%
5
Enstar Announces Reinsurance of Zurich Australia’s New South Wales Motor Vehicle Compulsory Third Party Insurance Business

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 February 2018 06:13:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180222.1 - EUROWEB1 - 2018-02-23 07:13:56 - 2018-02-23 06:13:56 - 1000 - Website: OKAY